HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

ausing bone marrow dysfunction and enlargement of the lymph nodes, liver and spleen. Standard front line therapy consists of alkylating agent based drug regimens. Fludarabine is the only approved drug for the treatment of patients who have failed alkylating agents. No approved therapy is available for patients who fail fludarabine therapy.

CAMPATH appears to work in CLL by depleting malignant CLL cells, which bear the CD52 antigen. CAMPATH is a humanized monoclonal antibody which is directed against the CD52 antigen found on normal and malignant lymphocytes, on normal macrophages and monocytes, but has not been detected on hematopoietic stem cells.

CAMPATH therapy is associated with significant lymphopenia. The lymphopenia resolves in some, but not all, patients over weeks to months after cessation of CAMPATH therapy.

"Early studies suggested the promise of CAMPATH. This study appears to confirm the decision to submit a BLA to the FDA," said Kanti R. Rai, M.D., Chief, Division Hematology-Oncology, Long Island Jewish Medical Center. "CAMPATH may very well become the next new and promising monoclonal antibody therapy for patients with cancer. For our patients with CLL, CAMPATH may change the expectation from one of relentlessly progressive deterioration on palliative therapies to the hope of extended survival," said Dr. Rai, who is also one of the trial's principal investigators and an internationally recognized expert in CLL.

ILEX and LeukoSite are developing CAMPATH through a joint venture that was established in May 1997. Clinical trials in the treatment of non-Hodgkin?s lymphoma, CLL, and other malignancies expressing CD52 are being planned.

"CAMPATH is the most advanced of ILEX's nine compounds and we are anxious to make it available to patients," said Richard L. Love, president and chief executive officer of ILEX.

ILEX Oncology, Inc. is a drug development company focused exclusively on accelerated development of drugs fo
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:8/31/2015)... TN (PRWEB) , ... August 31, 2015 , ... ... urgent care and accessible primary care, is enhancing its existing presence in Tennessee ... in Knoxville. The location is the company’s second in Knoxville, sixteenth in Tennessee, ...
(Date:8/31/2015)... ... August 31, 2015 , ... The more hours young adults spend ... mass index and bigger waist circumference, a 15-year analysis by the University of Pittsburgh ... in later years, indicating that young adulthood is an important time to intervene and ...
(Date:8/31/2015)... York (PRWEB) , ... August 31, 2015 , ... With ... when play-offs and the World Series will dominate the sports world. Fans desire nothing ... eventually advance to the final series. For children, especially those who are too young ...
(Date:8/31/2015)... ... 31, 2015 , ... Castle Dermatology Institute now welcomes San Fernando Valley ... graduate of the University of California, Los Angeles. He graduated summa cum laude with ... California, Irvine Medical School. As a nationally recognized Regents Scholar, Dr. Ghasri was given ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... 2015 in September by sharing the facts about the role of heredity in ... BRCA2 genetic mutations because of Angelina Jolie Pitt’s decisions to have both her ...
Breaking Medicine News(10 mins):Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:Watching More TV as a Young Adult Predicts Obesity 2Health News:Watching More TV as a Young Adult Predicts Obesity 3Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 2Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 3Health News:Foundation for Women’s Cancer Alerts Women to the Facts About the Role of Heredity in Gynecologic Cancers 4
(Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... Regen BioPharma, Inc. (OTCBB: RGBP) and ... means of delivering its patented (US Patent 8,263,571) ... utilizing a clinically approved formulation as delivery system.  ... gene silencing therapeutics in which the gene silencing ... body.  By utilizing a local delivery system, potential ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
Cached News: